Personalized medicine: Harnessing the allergy cascade to disrupt solid tumors

Harnessing the allergy cascade to target the extracellular matrix of solid tumors represents a frontier in immuno-oncology. Building upon advances in allergen-specific immunoglobulin E monoclonal antibodies and hyperallergenic skin creams, this approach leverages targeted degranulation to remodel the tumor microenvironment, enhance immune cell infiltration, and induce tumor cytotoxicity. This review examines the mechanistic rationale and emerging evidence for Passive Degranulation Cancer Immunotherapy.